**BACKGROUND**

Varicella-zoster virus (VZV), also known as human herpesvirus-3 (HHV-3), is associated with two distinct diseases: childhood chickenpox (varicella) and shingles (zoster). VZV becomes dormant in sensory ganglia and may reactivate decades later to produce zoster (shingles) or herpes zoster. VZV is enveloped in the trans-Golgi network (TGN). Glycoprotein I (gI) is required within the TGN for VZV envelopment and for efficient membrane fusion during VZV replication. The C-terminal domain of gI is required to segregate viral and cellular proteins in enveloping TGN cisternae. The amino-terminus of mature gI is required for glycoprotein E (gE)-gI complex formation by the external domains of VZV gE and gI. gE is a major component of the virion envelope and can be found complexed with glycoprotein I on the infected host cell surface. gE expression is activated by IE4 and IE62. VZV gI is required for replication of the virus in Vero cells, for efficient replication of the virus in nonhuman cells and for normal processing of gE.

**APPLICATIONS**

VZV gE (9C8) is recommended for detection of glycoprotein E of varicella zoster virus by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) and immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

Molecular Weight of VZV gE: 78 kDa.

**REFERENCES**


**SOURCE**

VZV gE (9C8) is a mouse monoclonal antibody raised against VZV infected cell extract.

**PRODUCT**

Each vial contains 100 µg IgG, kappa light chain in 1.0 ml of PBS with <0.1% sodium azide and 0.1% gelatin.

**STORAGE**

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

**RECOMMENDED SUPPORT REAGENTS**

To ensure optimal results, the following support reagents are recommended:


**SELECT PRODUCT CITATIONS**


**RESEARCH USE**

For research use only, not for use in diagnostic procedures.